Abstract
Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence
Original language | English (US) |
---|---|
Pages (from-to) | 1757-1760 |
Number of pages | 4 |
Journal | Journal of Thoracic Oncology |
Volume | 6 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2011 |
Keywords
- AT-101
- Extensive-stage small cell lung cancer
- Gossypol
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine